AI Article Synopsis

  • Patients with autoimmune diseases, particularly those with inflammatory bowel disease (IBD), face a higher risk of metabolic syndrome (MetS) and cardiovascular disease (CVD), yet research on this is limited.
  • A retrospective study examining data from the National Inpatient Sample over five years found that while IBD patients had lower overall prevalence of MetS components compared to non-IBD patients, ulcerative colitis (UC) patients had a higher prevalence than those with Crohn's disease (CD).
  • The study demonstrated that higher metabolic scores associated with MetS components were linked to increased risks of acute coronary syndrome and arrhythmias, with significant odds ratios indicating a strong correlation between MetS and heart failure in both IBD types.

Article Abstract

: Patients with autoimmune diseases experience a higher burden of metabolic syndrome (MetS) and cardiovascular disease (CVD). There is a paucity of data regarding MetS in patients with inflammatory bowel disease (IBD) and its impact on CVD. In this retrospective study, we aimed to evaluate the prevalence of MetS components in IBD patients, as well as their association with acute coronary syndrome (ACS), heart failure and arrhythmias. : After pooling 5 years of data from the National Inpatient Sample (NIS) Database (2016-2020), we compared traditional cardiovascular risk factors between IBD and non-IBD patients. We then investigated the association between MetS (represented by a calculated metabolic score (CMS) ranging from 0 to 4, based on the presence or absence of hypertension, obesity, dyslipidemia and type II diabetes) and CVD, separately for Crohn's disease (CD) and ulcerative colitis (UC) patients. : The prevalence of the different MetS components was found to be lower in IBD patients compared to non-IBD patients. Comparing CD (n = 806,875) and UC (n = 575,925) identified a higher prevalence of MetS components in UC. Higher CMS was positively associated with ACS and arrhythmias in both CD and UC. This association was evident in heart failure, with the odds ratio increasing from 2.601 for CMS = 1 to 6.290 for CMS = 4 in UC patients and from 2.622 to 5.709 in CD patients. : Our study highlights the positive association between traditional components of MetS and CVD in IBD patients. Our findings suggest that chronic inflammation explains only partially the CVD burden in hospitalized IBD patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11594857PMC
http://dx.doi.org/10.3390/jcm13226908DOI Listing

Publication Analysis

Top Keywords

ibd patients
16
patients
12
prevalence mets
12
mets components
12
metabolic syndrome
8
patients inflammatory
8
inflammatory bowel
8
bowel disease
8
heart failure
8
non-ibd patients
8

Similar Publications

Inflammatory bowel diseases during the COVID-19 pandemic.

Prz Gastroenterol

September 2024

Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, The Children's Memorial Health Institute, Warsaw, Poland.

Since the beginning of the COVID-19 pandemic in 2020, the safety of those with compromised immune systems and chronic disease has been of particular concern for health care providers. Inflammatory bowel diseases (IBD) are chronic, incurable conditions of digestive system with unknown aetiology, but one of the causes is disordered immune response. Medical therapies most frequently used in IBD are immune suppressing or modifying with the rising use of biologic treatment.

View Article and Find Full Text PDF

Analysis of risk factors of infection in patients with inflammatory bowel disease.

Prz Gastroenterol

September 2024

Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Unit, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland.

Introduction: infection (CDI) is one of the most important challenges in contemporary gastroenterology. However, data from CDI studies are sometimes contradictory.

Aim: To analyse the risk factors for CDI in patients with inflammatory bowel disease (IBD).

View Article and Find Full Text PDF

Background: Inflammatory bowel disease (IBD) occurs in up to 70%-80% of patients with primary sclerosing cholangitis (PSC). Oral vancomycin therapy (OVT) has been reported to be effective in the treatment of IBD associated with PSC (IBD-PSC).

Objectives: To examine the effectiveness and safety of OVT in the treatment of IBD-PSC by performing a systematic review and pooled analysis of the literature.

View Article and Find Full Text PDF

Background: Inflammatory bowel disease (IBD), which affects over 2.3 million people in the USA, involves chronic gut inflammation and can lead to cardiovascular complications, including pericarditis. Whether pericarditis in IBD patients is caused by medication, or by the disease itself, remains unclear.

View Article and Find Full Text PDF

Introduction: Biologic therapies treat patients with moderate to severe inflammatory bowel disease (IBD). This study aims to investigate the demographics of biologic therapy use and its association with patient characteristics, a topic that has not yet been thoroughly assessed in our region.

Methods: Electronic health record data from June 1, 2021, to May 31, 2023, were collected at a tertiary care IBD center in Kuwait.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!